Abeona Therapeutics Inc. (ABEO)

Market Cap	168.77M
Revenue (ttm)	3.50M
Net Income (ttm)	-76.66M
Shares Out	40.96M
EPS (ttm)	-3.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	153,633
Open	4.150
Previous Close	4.200
Day's Range	4.100 - 4.220
52-Week Range	2.830 - 9.010
Beta	1.52
Analysts	Strong Buy
Price Target	21.00 (+409.71%)
Earnings Date	Aug 6, 2024

About ABEO

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AI...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 19, 1980
• Employees: 84
• Stock Exchange: NASDAQ
• Ticker Symbol: ABEO

Financial Performance

In 2023, ABEO's revenue was $3.50 million, an increase of 147.52% compared to the previous year's $1.41 million. Losses were -$54.19 million, 24.6% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for ABEO stock is "Strong Buy." The 12-month stock price forecast is $21.0, which is an increase of 409.71% from the latest price.

Price Target

$21.0

(409.71% upside)

Analyst Consensus: Strong Buy